Bi-ventricular assist
This article was originally published in The Gray Sheet
Executive Summary
Biophan Technologies will direct the development, regulatory approval and marketing of Myotech's Myo-Vad minimally invasive bi-ventricular assist device. Myo-Vad is based on Myotech's Direct Mechanical Ventricular Assist (DMVA) technology - a flexible polymer cup installed around the heart through a small incision in about three minutes. The cup, featuring a pneumatically activated liner connected to a control line, compresses and expands to support both ventricles of the heart. The technology has been tested in over 700 animals...
You may also be interested in...
Biophan, Siemens sign pact
Development and commercialization of magnetic resonance imaging technologies is the goal of a new research collaboration inked between Biophan Europe and Siemens' MRI division. The deal follows Biophan's successful development of an MRI system to visualize implanted medical devices, such as heart valves, and Siemens' unveiling of a new MRI scanning technology, the 1.5 T wide-aperture Magnetrom Espree (1"The Gray Sheet" Sept. 19, 2005, In Brief)...
FDA’s New Dataset Aims To Assist Labs In Assessing Medical Device Biocompatibility
The US FDA’s device center has unveiled a new public dataset designed to assist chemistry laboratories in ensuring the robustness of chemical characterization methods used to assess the biocompatibility of medical devices.
Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line
The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.